Company news
Nuvectis Pharma, Inc. news in 2024
Nuvectis Pharma, Inc.'s news releases, calls and decks from 2024, newest first.
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
December 9, 2024
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
November 13, 2024
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
November 4, 2024
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
October 22, 2024
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 6, 2024
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
August 28, 2024
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
August 5, 2024
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
May 15, 2024
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
May 6, 2024
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
April 7, 2024
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 18, 2024
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 14, 2024
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
March 13, 2024
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
March 4, 2024
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 8, 2024
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024